A Similar Phase I Study on the Pharmacokinetics and Safety of Single-dose and Parallel Comparisons in Patients With Advanced NSCLC Treated With Recombinant Humanized Anti-PD-1 Monoclonal Antibody (JS001) Before and After Process Change
Phase of Trial: Phase I
Latest Information Update: 23 Mar 2018
At a glance
- Drugs JS 001 (Primary)
- Indications Non-small cell lung cancer
- Focus Pharmacokinetics
- Sponsors Shanghai Junshi Biosciences
- 17 Mar 2018 Planned End Date changed from 30 Apr 2018 to 30 Jul 2018.
- 17 Mar 2018 Planned primary completion date changed from 28 Feb 2018 to 28 Jun 2018.
- 01 Feb 2018 Planned primary completion date changed from 30 Jan 2018 to 28 Feb 2018.